<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595059</url>
  </required_header>
  <id_info>
    <org_study_id>M16-573</org_study_id>
    <nct_id>NCT03595059</nct_id>
  </id_info>
  <brief_title>A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety,&#xD;
      pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with&#xD;
      paclitaxel or docetaxel.&#xD;
&#xD;
      In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155&#xD;
      monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b).&#xD;
&#xD;
      In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination&#xD;
      therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory&#xD;
      (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or&#xD;
      docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer&#xD;
      (NSCLC) and breast cancer (Part 2b).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">September 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD and/or RPTD of ABBV-155</measure>
    <time_frame>Up to approximately 21 days after initial dose of study drug</time_frame>
    <description>The Maximum Tolerated Dose (MTD) and/or the Recommended Phase Two Dose (RPTD) of ABBV-155 will be determined during the dose escalation phase (Part 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 to 6 months</time_frame>
    <description>ORR is defined as the percentage of participants with documented best response partial response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>DOR is defined as the number of days from the date of first documented response (PR or better) to the date of the first documented disease progression (PD) or death due to disease, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response (CR)</measure>
    <time_frame>Up to approximately 2 to 6 months</time_frame>
    <description>CR is defined as the percentage of participants with documented best response CR according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>PFS is defined as the number of days from the date of first dose of study drug to the date of the first documented PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 12 months after last dose of study drug</time_frame>
    <description>OS is defined as the number of days from the date of first study drug to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>Maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>Time to maximum plasma concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Rate constant of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>Terminal phase elimination rate constant of ABBV-155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>AUC from time 0 to infinite time (AUCinf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF Change from Baseline</measure>
    <time_frame>Up to approximately 8 days</time_frame>
    <description>QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level of ABBV-155 Monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ABBV-155</measure>
    <time_frame>Up to approximately 48 days</time_frame>
    <description>Terminal elimination half-life (t1/2).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Escalation 1a: ABBV-155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ABBV-155 (various doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation 1b: ABBV-155 + paclitaxel or docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion 2a: ABBV-155 in SCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion 2b: ABBV-155 + docetaxel in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-155</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Escalation 1a: ABBV-155</arm_group_label>
    <arm_group_label>Escalation 1b: ABBV-155 + paclitaxel or docetaxel</arm_group_label>
    <arm_group_label>Expansion 2a: ABBV-155 in SCLC</arm_group_label>
    <arm_group_label>Expansion 2b: ABBV-155 + docetaxel in NSCLC</arm_group_label>
    <arm_group_label>Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Escalation 1b: ABBV-155 + paclitaxel or docetaxel</arm_group_label>
    <arm_group_label>Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Escalation 1b: ABBV-155 + paclitaxel or docetaxel</arm_group_label>
    <arm_group_label>Expansion 2b: ABBV-155 + docetaxel in NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologic or cytologic diagnosis of a malignant solid tumor.&#xD;
&#xD;
          -  Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell&#xD;
             lung cancer (SCLC) with tumors that express B7H3 above a given threshold per central&#xD;
             laboratory testing; participants enrolled to Part 2b (combination therapy, dose&#xD;
             expansion) must have either NSCLC or HR-positive/HER2-negative breast cancer with&#xD;
             tumors that express B7H3 above a given threshold per central laboratory testing.&#xD;
&#xD;
          -  Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             criteria.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to&#xD;
             2.&#xD;
&#xD;
          -  Failure of at least 1 prior systemic chemotherapy including all available standard&#xD;
             therapies for participants in the dose-escalation phase (Parts 1a and 1b).&#xD;
&#xD;
          -  All participants with breast cancer for subjects in the dose-expansion phase (Part 2b&#xD;
             only) must have the following:&#xD;
&#xD;
          -  locally advanced or metastatic HR-positive/HER2-negative breast cancer after failing&#xD;
             cyclin-dependent kinase (CDK)4/6 inhibitor-based therapy.&#xD;
&#xD;
          -  HR-positivity and HER-2-negativity should be confirmed based on American Society of&#xD;
             Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria.&#xD;
&#xD;
          -  All participants with non-small cell lung cancer (NSCLC) for participants in the&#xD;
             dose-expansion phase (Part 2b only) must have R/R NSCLC after at least 1 line of&#xD;
             therapy.&#xD;
&#xD;
          -  All participants with SCLC in the dose-expansion phase (Part 2a only) must have R/R&#xD;
             SCLC from at least 1 line of therapy which includes a platinum-based therapy with or&#xD;
             without an anti-PD-1/PD-L1 therapy.&#xD;
&#xD;
          -  All participants with either breast cancer or NSCLC must have the following if exposed&#xD;
             to prior taxane-based therapy: no history of taxane allergy (Part 1b and Part 2b&#xD;
             only); and disease that has relapsed or progressed at least 2 months after most recent&#xD;
             exposure to any taxane-based therapy.&#xD;
&#xD;
          -  Available tumor tissue suitable for immunohistochemistry testing.&#xD;
&#xD;
          -  Adequate kidney, liver, and hematologic laboratory values as described in the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated brain or meningeal metastases (participants with a history of metastases may&#xD;
             be eligible based on details described in the protocol).&#xD;
&#xD;
          -  Grade 2 or higher peripheral neuropathy (only applies to participants who would&#xD;
             receive taxane therapy).&#xD;
&#xD;
          -  Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except&#xD;
             alopecia.&#xD;
&#xD;
          -  Known active infection of hepatitis B, hepatitis C, or human immunodeficiency virus&#xD;
             with exceptions as described in the protocol.&#xD;
&#xD;
          -  Recent history (within 6 months) of congestive heart failure (defined in the&#xD;
             protocol), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological&#xD;
             or surgical intervention, pericardial effusion, or pericarditis.&#xD;
&#xD;
          -  Any history of hypersensitivity to any ingredients of ABBV-155 will be excluded. For&#xD;
             combination therapy only (Parts 1b and 2b), no history of serious allergic reaction to&#xD;
             any taxane or any ingredients used in taxane formulation (e.g., cremaphor).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Main /ID# 214024</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group /ID# 201568</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center-West Hollywood /ID# 204267</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center /ID# 208365</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University, Yale Cancer Center /ID# 201542</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-3206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute - Orlando /ID# 227242</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 201563</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Med Cnt /ID# 215095</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University /ID# 201320</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 201564</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital /ID# 226852</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Marcus Ave /ID# 204376</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042-2060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 201577</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Cleveland /ID# 201567</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, Stephenson Cancer Center /ID# 206820</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute at Rhode Island Hospital /ID# 204256</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903-4923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center /ID# 201575</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 214168</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center /ID# 201558</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology /ID# 204893</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute /ID# 213838</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre /ID# 204539</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 230812</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 230813</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 215130</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 215003</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek /ID# 222260</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum /ID# 222341</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 225220</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 222357</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pan American Center for Oncology Trials, LLC /ID# 232128</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital /ID# 214062</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 206304</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 205673</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Relapsed and/or Refractory Solid Tumors</keyword>
  <keyword>ABBV-155</keyword>
  <keyword>Taxane</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>breast cancer</keyword>
  <keyword>non-small cell lung cancer (NSCLC)</keyword>
  <keyword>small cell lung cancer (SCLC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

